Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 6 | 2025 | 1277 | 1.320 |
Why?
|
| Pericardial Effusion | 1 | 2025 | 72 | 0.870 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 688 | 0.810 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 49 | 0.760 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 130 | 0.730 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 154 | 0.710 |
Why?
|
| Fanconi Anemia | 1 | 2018 | 48 | 0.540 |
Why?
|
| alpha-Fetoproteins | 1 | 2018 | 125 | 0.520 |
Why?
|
| SOS1 Protein | 1 | 2016 | 1 | 0.510 |
Why?
|
| Noonan Syndrome | 1 | 2016 | 31 | 0.490 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 861 | 0.480 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2016 | 50 | 0.480 |
Why?
|
| Gene Duplication | 1 | 2016 | 358 | 0.440 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 242 | 0.420 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 634 | 0.390 |
Why?
|
| Interferon-gamma | 1 | 2015 | 550 | 0.390 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 501 | 0.370 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 951 | 0.270 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 190 | 0.210 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 26 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2025 | 152 | 0.200 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2024 | 150 | 0.200 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 148 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 57 | 0.190 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17552 | 0.170 |
Why?
|
| Hematologic Neoplasms | 1 | 2025 | 314 | 0.170 |
Why?
|
| Child, Preschool | 5 | 2025 | 14977 | 0.160 |
Why?
|
| Recurrence | 1 | 2023 | 1476 | 0.150 |
Why?
|
| Child | 6 | 2025 | 26160 | 0.150 |
Why?
|
| Texas | 2 | 2025 | 3644 | 0.150 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 306 | 0.150 |
Why?
|
| Incidence | 1 | 2025 | 3317 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 332 | 0.130 |
Why?
|
| Infant | 4 | 2025 | 13259 | 0.130 |
Why?
|
| Humans | 12 | 2025 | 130506 | 0.130 |
Why?
|
| Young Adult | 3 | 2025 | 10005 | 0.120 |
Why?
|
| Transplantation Conditioning | 3 | 2023 | 327 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2016 | 121 | 0.120 |
Why?
|
| Adolescent | 5 | 2025 | 20760 | 0.120 |
Why?
|
| ras Proteins | 1 | 2016 | 141 | 0.120 |
Why?
|
| CD28 Antigens | 1 | 2015 | 76 | 0.110 |
Why?
|
| CD40 Ligand | 1 | 2015 | 65 | 0.110 |
Why?
|
| CD3 Complex | 1 | 2015 | 95 | 0.110 |
Why?
|
| Coculture Techniques | 1 | 2015 | 230 | 0.110 |
Why?
|
| Biological Assay | 1 | 2015 | 106 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 319 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 372 | 0.100 |
Why?
|
| Risk Factors | 2 | 2025 | 10958 | 0.100 |
Why?
|
| Cell Survival | 1 | 2015 | 834 | 0.100 |
Why?
|
| Female | 5 | 2025 | 70401 | 0.090 |
Why?
|
| Alemtuzumab | 2 | 2023 | 89 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2101 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1874 | 0.080 |
Why?
|
| Cell Line | 1 | 2015 | 2558 | 0.080 |
Why?
|
| Male | 4 | 2025 | 64503 | 0.080 |
Why?
|
| Neoplasms | 1 | 2025 | 2979 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2466 | 0.070 |
Why?
|
| Phenotype | 1 | 2016 | 4478 | 0.060 |
Why?
|
| Biological Products | 1 | 2025 | 143 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2024 | 222 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 51 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 22 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 45 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2025 | 500 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 667 | 0.040 |
Why?
|
| Cytarabine | 1 | 2022 | 100 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 254 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2021 | 72 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 427 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 171 | 0.040 |
Why?
|
| Aged | 3 | 2025 | 20887 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 707 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 437 | 0.030 |
Why?
|
| Registries | 1 | 2024 | 1610 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5160 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 4866 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1268 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 6796 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1332 | 0.030 |
Why?
|
| Middle Aged | 2 | 2025 | 28401 | 0.020 |
Why?
|
| Adult | 2 | 2025 | 31142 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6434 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 12853 | 0.020 |
Why?
|